Guggenheim Maintains Buy Rating on Elevance Health, Sets $460 Target
Guggenheim maintained its Buy rating on Elevance Health and a $460 price target, implying 11.5% upside from the Oct. 9 close of $412.70.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.